C87499 Inhibitors
C87499 inhibitors are a class of chemical compounds that target and modulate the activity of the protein encoded by the Pramel32 gene. Pramel32 is a member of the PRAME (Preferentially Expressed Antigen in Melanoma) family, which is known to be involved in various cellular processes, including gene regulation and immune responses. The inhibitors within the C87499 class are specifically designed to bind to the Pramel32 protein, thereby altering its structure or function, which may lead to changes in downstream signaling pathways. These compounds have been characterized by their ability to affect the molecular mechanisms regulated by Pramel32, making them valuable tools for probing its role in cellular processes.
Research into C87499 inhibitors has focused on their specificity and efficacy in modulating Pramel32-associated pathways, which are often critical in maintaining normal cellular function. The binding affinity and selectivity of these inhibitors for Pramel32 make them useful for studying the protein's interaction with other cellular components and for understanding its broader biological functions. Additionally, C87499 inhibitors serve as important molecular probes in research aimed at deciphering the regulatory mechanisms involving Pramel32. These inhibitors are vital for studying the consequences of modulating Pramel32 activity, providing insights into the role of this protein in gene expression, cell proliferation, and other fundamental biological processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
Inhibits NEDD8-activating enzyme (NAE), blocking the activation of cullin-based ubiquitin ligases, including Cul2-RING. Disruption of this activation may impact the Cul2-RING complex, potentially influencing Pramel32 ubiquitination and degradation. | ||||||
SNS-032 | 345627-80-7 | sc-364621 sc-364621A | 5 mg 10 mg | $169.00 $262.00 | ||
Cyclin-dependent kinase (CDK) inhibitor affecting cell cycle progression. Inhibition of CDKs may indirectly influence Cul2-RING complex function and subsequently impact Pramel32 regulation through ubiquitination processes. | ||||||
MLN 8054 | 869363-13-3 | sc-484828 | 5 mg | $398.00 | ||
Inhibits Aurora A kinase, potentially influencing the Cul2-RING complex dynamics. Alterations in the complex may indirectly affect Pramel32 ubiquitination and turnover, highlighting the interconnected nature of the ubiquitin-proteasome system. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
BET bromodomain inhibitor affecting gene transcription. As Cul2-RING complexes can ubiquitinate certain transcription factors, JQ1 may indirectly influence Pramel32 through alterations in the ubiquitin-mediated regulation of transcription factors associated with Cul2-RING. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Exhibits anti-inflammatory properties and may modulate the Cul2-RING ubiquitin ligase complex indirectly. Changes in the complex could impact Pramel32 ubiquitination and stability, suggesting a potential link between inflammation signaling and Pramel32 regulation. | ||||||
CC-401 | 395104-30-0 | sc-364748 sc-364748A | 2 mg 10 mg | $331.00 $1060.00 | 4 | |
JAK2 inhibitor impacting the JAK-STAT signaling pathway. As Cul2-RING complexes can ubiquitinate proteins involved in the JAK-STAT pathway, inhibition of JAK2 may indirectly affect Pramel32 regulation through alterations in the ubiquitin-mediated turnover of pathway components. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Immunomodulatory drug impacting the E3 ubiquitin ligase complex. By affecting the ubiquitin-proteasome system, lenalidomide may indirectly influence Pramel32 ubiquitination and degradation, potentially connecting immune modulation with Pramel32 regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Proteasome inhibitor disrupting protein degradation pathways. Inhibition of the proteasome may indirectly affect Pramel32 by preventing its ubiquitin-mediated degradation, providing insights into the potential role of the Cul2-RING ubiquitin ligase complex in Pramel32 regulation and stability. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-βRI kinase inhibitor impacting the TGF-β signaling pathway. As TGF-β signaling involves the Cul2-RING ubiquitin ligase complex, SD-208 may indirectly influence Pramel32 regulation through alterations in the ubiquitin-mediated turnover of proteins associated with the TGF-β pathway. | ||||||